DepoMed Urges Holders to Reject Horizon Offer
September 14 2015 - 10:20AM
Dow Jones News
DepoMed Inc. said its board urged its shareholders to reject
Horizon Pharma PLC's unsolicited bid to acquire the company in a
share-exchange offer, reiterating that the deal significantly
undervalues the company.
Depomed holders have been offered 0.95 Horizon share for each
Depomed share held, an offer valued at roughly $27.54 a share as of
Friday's close.
Horizon first made an all-stock offer to buy Depomed in a letter
sent May 27, and then went public with an increased proposal
mid-July after the previous offer was rejected by Depomed's
board.
Horizon also has been seeking to replace the Depomed board.
A Horizon spokesman wasn't immediately available to comment on
Monday.
Depomed's board has repeatedly said Horizon's takeover attempt
is "not in the best interest" of the company, given that it is in a
period of significant growth and is expected to benefit from its
recent acquisition of the U.S. rights to pain killer Nucynta from
Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson.
In its news release Monday, DepoMed said it thinks Nucynta has
the potential to exceed $1 billion in annual net sales. The company
also said that during the first quarter DepoMed sold the drug,
Nucynta sales reached $56.7 million.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 14, 2015 10:05 ET (14:05 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024